GlycoMimetics Inc (NASDAQ:GLYC)

8.15
Data as of Aug 29
 +0.13 / +1.62%
Today’s Change
6.02
Today|||52-Week Range
18.99
--
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$154.0M

Company Description

GlycoMimetics, Inc. is a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Gaithersburg, MD.

Contact Information

GlycoMimetics, Inc.
401 Professional Drive
Gaithersburg Maryland 20879
P:(240) 243-1201
Investor Relations:
(240) 243-1207

Employees

Shareholders

Individual stakeholders54.42%
Other institutional14.61%
Mutual fund holders12.95%

Top Executives

Rachel K. KingPresident, Chief Executive Officer & Director
Brian M. HahnChief Financial Officer & Head-Media Relations
John L. MagnaniSecretary, Director, Chief Scientific Officer & VP
Helen M. ThackrayChief Medical Officer & VP-Clinical Development
Armand GirardVice President-Corporate Development

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.